Elanco Animal Health Incorporated (NYSE: ELAN) today announced that Prevacent® PRRS has been licensed for use in sows and gilts against the reproductive form of porcine reproductive and respiratory syndrome (PRRS), when vaccinated six weeks prior to breeding. Prevacent, a modified-live PRRS vaccine, had previously been approved in the fall of 2018 for use in pigs two weeks of age and older, and had shown to be effective against PRRS respiratory disease.
PRRS cost the U.S. swine herd industry $664 million per year from 2005 to 2010, translating into $1.8 million per day or $114.71 per sow annually.1 PRRS increases mortality and reduces growth performance, which reduces sustainability and compromises herd well-being.2 With new approval for use in sows and gilts, Prevacent PRRS control expands use across production phases.
“With limited post-vaccination growth depression and the contemporary lineage, Elanco is excited to offer the industry an expansion of the Prevacent label to include a reproductive claim. We look forward to working with veterinarians and producers as we work to improve control of PRRS,” said Dr. Mark Hammer, Elanco consulting veterinarian.
Additional pack and dose sizes of Prevacent will be available in the fall of 2020 for added flexibility and convenience across production segments. More information associated with Prevacent’s new sow indication can be found at ControlPRRS.com.
Prevacent was found to be safe for all gestational stages as shown by vaccination reactions comparable to controls and no adverse impacts on farrowing rate.3 Prevacent-vaccinated gilts also demonstrated a reduction in the duration and level of viremia, or the presence of the PRRS virus in the blood, as well as improvements in piglet viability and birth weight* compared to controls.4
Prevacent license approval in sows expands Elanco’s Full Value portfolio of swine products to manage disease challenges, minimize variation, and mitigate mortality to ultimately optimize pig health.